| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
|
Zhao, Yiming
|
|
2019
|
14 |
2 |
p. 169-178
|
artikel
|
| 2 |
Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis
|
Guo, Qianqian
|
|
2019
|
14 |
2 |
p. 139-148
|
artikel
|
| 3 |
Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib
|
Su, Yudong
|
|
2019
|
14 |
2 |
p. 159-168
|
artikel
|
| 4 |
EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR
|
Buder, Anna
|
|
2019
|
14 |
2 |
p. 197-203
|
artikel
|
| 5 |
Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies
|
Lucas, Fabienne
|
|
2019
|
14 |
2 |
p. 125-138
|
artikel
|
| 6 |
Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study
|
Hong, Xiaonan
|
|
2019
|
14 |
2 |
p. 149-158
|
artikel
|
| 7 |
Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy
|
Takagi, Toshio
|
|
2019
|
14 |
2 |
p. 179-186
|
artikel
|
| 8 |
Rucaparib: A Review in Ovarian Cancer
|
Shirley, Matt
|
|
2019
|
14 |
2 |
p. 237-246
|
artikel
|
| 9 |
Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
|
Chen, Xiang
|
|
2019
|
14 |
2 |
p. 187-195
|
artikel
|
| 10 |
Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models
|
Yee, Pei San
|
|
2019
|
14 |
2 |
p. 223-235
|
artikel
|
| 11 |
The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies
|
Marquardt, Jens U.
|
|
|
14 |
2 |
p. 115-123
|
artikel
|
| 12 |
The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies
|
Marquardt, Jens U.
|
|
2019
|
14 |
2 |
p. 115-123
|
artikel
|
| 13 |
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System
|
Raschi, Emanuel
|
|
2019
|
14 |
2 |
p. 205-221
|
artikel
|
| 14 |
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System
|
Raschi, Emanuel
|
|
|
14 |
2 |
p. 205-221
|
artikel
|
Tijdschrift beschrijving